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1. Introduction 
1.1. Respiratory Tract Infections (RTIs) 
Respiratory tract infections (RTIs) are caused directly or indirectly by any infectious agent 
that implants and replicates in the respiratory tract, in the pulmonary parenchyma or onto 
pleural sierose and causes clinical syndromes with prevalent respiratory symptoms [1]. 
When the respiratory tract is only the first site of infection, patients show respiratory 
syndromes, but then symptoms involve the specific anatomic district target of the infectious 
agent, as we can see in some infectious disease: Measles, Scarlet fever, Mononucleosis, 
Meningococcal disease and Varicella. Even with these limitations RTIs are the most common 
infections in men and are a significant cause of morbidity and mortality in both developing 
and developed countries among infants, youngsters and elderly people, and are the first 
cause of temporary invalidation (absence from work or school), visiting emergency service 
and family doctor consultancies during the winter season, independently from the age [2]. 
so they are a great socioeconomic and medical burden. In 2010, the World Health 
Organization (WHO) estimated that RTIs caused about 3 million deaths worldwide, 
including developed countries, being the first cause of child mortality [3]. Respiratory 
infections are common in both hospital and community settings. The third national 
prevalence survey conducted in 2006 found that infections of the lower respiratory tract 
(LRTI, not pneumonia) and pneumonia together accounted for 19.9 percent of the 
Healthcare Associated Infections (HCAIs) in acute hospitals. It I important also to consider 
the hospital-acquired infections affecting the respiratory tract that cause considerable 
morbidity and mortality. This type of respiratory infections generally affects those who are 
affected from serious diseases [4]. RTIs can be classified in, infections of the upper 
respiratory tract (URIs), which affect the nose, sinuses and throat (common cold, tonsillitis, 
sinusitis, laryngitis, influenza) and infections of the lower respiratory tract (LRTIs), which 
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affect the airways and lungs (influenza, bronchitis, pneumonia, bronchiolitis, tuberculosis, 
that is a persistent bacterial infection of the lungs). LRTIs include two serious conditions – 
acute bronchitis and pneumonia: 
Acute bronchitis (inflammation of the bronchi) is an acute respiratory infection in which the 
dominant symptom is coughing without localized infection. It must not not be confused 
with chronic bronchitis, which is a chronic obstructive pulmonary disease (COPD). Acute 
bronchitis is usually an infection that is community-acquired and typically it arises as a 
complication of URI caused by a virus, when bacterial infection supervenes. Children that 
seem prone to bronchitis generally have poor living conditions (overcrowding,poor hygiene 
and poor nutrition) and the respiratory disease may be exacerbated by maternal smoking, 
especially during pregnancy. It I reported that individuals who have experienced childhood 
bronchitis are at risk of developing further symptoms during their teenage years if they then 
smoke [5]. Pneumonia (inflammation of the lung) is a serious condition, that caused may 
death after RTI, especially in older adults and infants. It may be acquired in hospital or the 
community. The alveoli become filled with pus, air is excluded, and the lung is said to be 
‘consolidated’.In bronchopneumonia, consolidation is widely distributed; in lobar 
pneumonia,it is localized [6]. In the community, bacterial pneumonia is most frequently 
caused by Streptococcus pneumonia that infects most commonly people with pre-
existinghealth problems, frequently developing as a complication of some other RTI (for 
example influenza or measles). The establishment of a pharmacological treatment is 
complicated because some strains of Streptococcus pneumoniae are now resistant to penicillin, 
so vaccination has been recommended in the UK since 2003. The pneumococcal vaccine is 
part of the childhood immunization program and it is also recommended to people over 65 
years of age. It is also recommended for people following splenectomy and those with 
dysfunction of the spleen, sickle cell disease, coeliac disease, chronic renal disease, chronic 
respiratory disease, chronic heart conditions, liver disease, diabetes mellitus, 
immunosuppression and HIV. After vaccination, about 80 per cent of healthy adults 
develop a good antibody response within three weeks. Other bacteria responsible for 
community-acquired pneumonia include Mycoplasma pneumoniae, Haemophilus influenzae, 
Legionella pneumophila and Staphylococcus aureus, including the strain that produces the 
Panton–Valentine leukocidin toxin [7]. It I mandatory also to consider hospital acquired 
pneumonia. It mainly affects critically ill and postoperative patients. Risk factors include 
obesity, impaired consciousness, a history of smoking and underlying respiratory disease. In 
hospital, bacteria, viruses or fungi can cause pneumonia, but most hospital-acquired 
pneumonia is caused by S. aureus and Gram-negative opportunists [8]. URIs that involve the 
nasal passages, pharynx, tonsils and epiglottis are minor infections acquired in the 
community and are caused by viruses. URIs can, however, have serious consequences for 
the very young and older adults. They also account for a high proportion of days lost from 
work and school, so their impact on the health of individuals and their social and economic 
consequences should not be dismissed. The nasal discharge associated with colds contains 
viral particles, dead cells from the nasal mucosa and bacteria, but these are of the same type  
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as are present in health. Bacterial invasion of the damaged epithelium is rare, and antibiotics 
are seldom required. Acute ear infection occurs as a complication with up to 30 percent of 
URIs. Because most URIs are self-limiting, their complications are more important than the 
infections, mastoiditis and other complications of URIs account for nearly 5 percent of all 
URI worldwide leading to hearing impairment or deafness most of the times in developing 
countries where there is limited access to adequate medical treatments. RTIs are 
extraordinary frequent because of a great number of antigenically distinct aetiological 
agents, their great diffusion and the short period of immunization. Moreover the anatomic 
structure of the respiratory tract shows high variable physicochemical parameters such as 
temperature, pH, and humidity that assurance a great number of habitat for various 
microorganisms. Moreover the respiratory tract is directly connected to the external 
environment and it is continuously crossed by the airflow that frequently contains irritant 
agents (atmospheric contaminants, cigarette smoke, cold air, fines) that may injure the local 
mucosa end predispose to the implantation of microorganisms. Fortunately there is a huge 
amount of mechanisms of defense that preserve the integrity of this anatomic site, the 
nasopharyngeal lymphatic system, ciliary cells, salivary lisozima, antibodies, interferons 
and pulmonary macrophafges. The infectious agents of RTIs can be viruses, bacteria, fungi 
and protozoa, but they are usually caused by a virus [1, 2]. Bacterial agents causing RTIs can 
implant directly onto the mucosa of the respiratory tract, but more frequently they 
superinfect a tract of mucosa previously injured by a virus. Streptococcus pneumoniae, 
Haemophilus influenzae, and Moraxella catarrhalis are the most common organisms that cause 
the bacterial superinfection of viral acute sinusitis [8]. The sequence viral-bacterial infection 
is very frequent and must be considered to establish an appropriate pharmacological 
treatment. Parasitic infections of the respiratory tract occur worldwide among both 
immunocompetent and immunocompromised patients and may affect the respiratory 
system in a variety of ways. The most common parasites involved are, Ascariasis, Schistosoma 
and Toxoplasma gondii. Since the clinical presentations and radiographic findings of several 
of these diseases may mimic tuberculosis and malignancy it is important to consider 
parasitic infections in the differential diagnosis of such respiratory syndromes. If identified 
early, most parasitic respiratory diseases are curable with medical or surgical treatments [9]. 
RTIs are transmitted by airflow, pathogens enter the organism trough the upper respiratory 
tract and sometimes trough the conjunctivae, that have been infected by direct contact 
especially for viruses, or trough vectors, whereas the elimination of the infecting particles 
takes place trough cough. Rarely the respiratory tract can be reached by circulating 
microorganisms in blood. The reservoir for the majority of RTIss are infected humans that 
guarantee an optimal environment for the survival of the infecting agent, but some 
microorganisms that occasionally infect humans have animal reservoir; for example in 2002, 
a new Coronavirus (CoV) emerged in the People's Republic of China, associated with a 
severe acute respiratory syndrome (SARS) and mortality in humans. The epidemic rapidly 
spread throughout the world before being contained in 2003, although sporadic cases 
occurred thereafter in Asia. The virus was thought to be of zoonotic origin from a wild 
animal reservoir (Himalayan palm civets, Paguma larvata), but the definitive host is still 
unknown [10]. RTIs are generally epidemic because they are very contagious, generally they 
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are more frequent during autumn and winter when atmospheric pollution is higher and 
permanence indoor increases. Acquired immunity after RTIs is generally short because the 
majority of the most common aetiological agents are ineffective immunogens; the 
immunological response to RTIs generally produces initially IgM and after IgG, so that the 
presence of IgG has a diagnostic value only if it increases for times or is very high. During 
RTIs many viral and bacterial immunogens induce the production of secretory IgA that are 
released in to the muco where they compete for tissue receptors and link to microorganisms. 
The periodic genetic mutations of RTIs aetiological agents vanish both natural and acquired 
immunity; each time that genetic mutations that involve major antigens take place, 
especially for viruses, the diffusion of the infecting agent of RTIs becomes pandemic [11]. An 
example of immune evasion due to genetic variability is given by INFVs that are dynamic 
and are continuously evolving. INFVs can change in two different ways: antigenic drift and 
antigenic shift. Antigenic drift takes place continuously while antigenic shift happens only 
occasionally. INF A viruses undergo both kinds of changes; INF B viruses change only by 
the more gradual process of antigenic drift. Antigenic drift refers to small, gradual changes 
that occur through point mutations in the two genes that contain the genetic material to 
produce the main surface proteins, hemagglutinin (HA), and neuraminidase (NA). These 
point mutations occur unpredictably and result in minor changes to these surface proteins. 
Antigenic drift produces new virus strains that may not be recognized by antibodies to 
earlier INFVs strains. This is one of the main reasons why people can become infected with 
INFVs more than one time and why global surveillance is critical in order to monitor the 
evolution of human INFVs for selection of which strains should be included in the annual 
production of INF vaccine. In most years, one or two of the three virus strains in the INF 
vaccine are updated to keep up with the changes in the circulating INFVs. For this reason, 
the immunization against INF needs to be vaccinated every year. Antigenic shift refers to an 
abrupt, major change to produce a novel INFV A subtype in humans that was not currently 
circulating among people. Antigenic shift can occur either through direct animal (poultry)-
to-human transmission or through mixing of human influenza A and animal influenza A 
virus genes to create a new human influenza A subtype virus through genetic reassortment. 
Antigenic shift results in a new human INFV A subtype [12, 13].  
2. Viral RTIs 
At least two hundred different viruses can establish RTIs and they belong to the 
Adenoviridae, Orthomyxoviridae, Paramyxoviridae, Picornaviridae, Coronaviridae, Herpesviridae 
and Parvoviridae familes. Viruses the most frequently associated with RTIs are, Adenovirus 
(ADV), BoV, CoV, Enterovirus (ENTV), INFV A, B, C, Metapneumovirus (hMetV), 
Parainfluenza (IPV) viruses 1, 2, 3, 4, Rhinoviruses (RV), Respiratory Syncitial Viruses 
(RSV). While it is true that respiratory viruses place a greater burden on people in 
developing countries, these viruses are still a big health threat in the developed world, 
where over 100 million people have been killed INFV in the last century alone (Piralla et al. 
2011). In children, viruses are responsible for the majority of RTIs, with bacteria thought to 
be responsible for fewer than 15% of cases; acute pharyngitis is caused by viruses in more  
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than 70% percent of cases in young children, mild pharyngeal redness and swelling and 
tonsil enlargement are typical [2, 15]. The most pathogenetic viruses for humans are, INFV 
and RSV with high mortality rate in elderly people and infants respectively. INFVs have the 
highest evolution rate, being the INF A viruses those causing the most severe and expansive 
outbreaks. Genetic variations in INF A viruses usually lead to global epidemics or 
pandemics; the latest FluA (H1N1) outbreak in 2009 was originated by a variant INF A 
H1N1 of swine origin, classified by the World Health Organization (WHO) as level 6 alert, 
pandemic [16]. Viruses cause most URIs, with RVs accounting for the 25-30% of cases, IPV, 
ADV, RSV, INFV 25-35%, CoV 10% and ENTV (Coxsackievirus, CoxV) less than 5% [17]. 
Acute viral infections predispose to bacterial infections of the sinuses and middle ear, and 
aspiration of infected secretions and cells can result in LRIs. To date the most common 
causes of viral LRIs are RSVs. They tend to be highly seasonal, unlike PINFV, the next most 
common cause of viral LRIs. The epidemiology of influenza viruses in children in 
developing countries deserves urgent investigation because safe and effective vaccines are 
available. Before the effective use of measles vaccine, the Measles virus was the most 
important viral cause of respiratory tract–related morbidity and mortality in children in 
developing countries. ADVs are medium-sized (90-100 nm), non-enveloped icosohedral 
viruses with double-stranded DNA. There are over 50 types that are immunologically 
distinct that can cause infections in humans. ADVS are relatively resistant to chemical and 
physical agents and to adverse pH conditions and can live for a long time outside the body 
and most commonly cause respiratory illness. The symptoms of ADV infection can range 
from the common cold to pneumonia, croup, and bronchitis. Some ADVs types can cause 
other illnesses such as gastroenteritis, conjunctivitis, cystitis, and less commonly, 
neurological disease. Infants and people with weakened immune systems are at high risk for 
severe complications of ADV infection and some people infected with ADV can have 
ongoing infections in their tonsils, adenoids, and intestines that do not cause symptoms. 
They can shed the virus for months or years [18].Human bocavirus (hBoV), the second 
parvovirus potentially pathogenic to humans after Parvovirus B19 (Pb19), was discovered 
by PCR in respiratory samples collected from young children with respiratory diseases in 
Sweden in 2005. Since the first description of hBoV as a possible human pathogen of lower 
respiratory tract infections in children, it has been detected in at least 19 countries in the five 
continents. HBoV infections shows a variety of clinical symptoms; the most common 
symptoms in hBoV-infected children without coinfections are cough (85%), followed by 
rinorrhea (67%), fever (59%), difficulty in breathing (48%), diarrhea (16%), conjunctivitis 
(9%) and rash (9%), body temperature ranging from 37.5 to 40.2oC, wheezing; nausea, sore 
throat, headache and myalgia were also recorded in hBoV-infected children of older age and 
adults. The age distribution of hBoV-infected humans ranges from 10 days to 60 years, but 
hBoV was primarily detected in young children aged 6 months to 3 years. That a peak 
detection of hBoV is among children of 6 to 24 months of age [19]. CoVs (order Nidovirales, 
family Coronaviridae, genus Coronavirus) are a diverse group of large, enveloped, positive-
stranded RNA viruses that cause respiratory and enteric diseases in humans and other 
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animals. There are three groups of CoV; groups 1 and 2 contain mammalian viruses, while 
group 3 contains only avian viruses. Within each group, CoVs are classified into distinct 
species by host range, antigenic relationships, and genomic organization. The viruses can 
cause severe disease in many animals, and several viruses, including infectious bronchitis 
virus, feline infectious peritonitis virus, and transmissible gastroenteritis virus, are 
significant veterinary pathogens. Human coronaviruses (hCoVs) are found in both group 1 
(HCoV-229E) and group 2 (HCoV-OC43) and are responsiblefor ~30% of mild upper 
respiratory tract illnesses [19]. In March 2003, a novel CoV, SARS-CoV was discovered in 
association with cases of severe acute respiratory syndrome (SARS). The sequence of the 
complete genome of SARS-CoV has been now determined; it is 29,727 nucleotides in length, 
has 11 open reading frames, and the genome organization is similar to that of other CoVs. 
Phylogenetic analyses and sequence comparisons showed that SARS-CoV is not closely 
related to any of the previously characterized CoV. By late April 2003, over 4300 SARS cases 
and 250 SARS-related deaths were reported to WHO from over 25 countries around the 
world. Most of these cases occurred after exposure to SARS patients in household or 
healthcare settings. The incubation period for the disease is usually from 2 to 7 days. 
Infection is usually characterized by fever, which is followed a few days later by a dry, non-
productive cough, and shortness of breath. Death from progressive respiratory failure 
occurs in about 3% to nearly 10% of cases. Evidence of SARS-CoV infection has been 
documented in SARS patients throughout the world. SARSCoV RNA has frequently been 
detected in respiratory specimens, and convalescent-phase serum specimens from SARS 
patients contain antibodies that react with SARS-CoV [19]. Enteroviruses (ENTV) genus 
belongs to the Picornaviridae family positive single stand ssRNA viruses. Current taxonomy 
divides non-polio human ENTVs into four species (human ENTVs A to D), including a total 
of 108 serotypes. Individual serotypes have different temporal patterns of circulation and 
can be associated with different clinical manifestations. Although the majority of human 
ENTV infections remain asymptomatic, these viruses are associated with various clinical 
syndromes, ranging from minor febrile illness to severe and potentially fatal pathologies, 
including aseptic meningitis, encephalitis, myopericarditis, acute flaccid paralysis, and 
severe neonatal sepsis-like disease. ENTVs are responsible for a wide range URIs and LRTIs 
occurring in adults and infants. These viruses are considered as the third etiological cause of 
bronchiolitis in young infants aged 1-12 months. Moreover, several clinical case studies 
reported the etiological role of the Cox A16, the ENTV 71 and of a newly discovered 
genotype ENTV-104 in the development of acute or fatal pneumonia indicating that ENTVs 
belonging to species A to C can be responsible for severe LRTIs in immunocompetent 
infants or adults. Taking into account the recent epidemiological and clinical data and 
because of frequent mutations and intra-species enteroviral RNA genomic recombination 
events, the respiratory strains of ENTV are considered also as potential agents of emerging 
infectious diseases in human populations [21]. There are three types of INFV: A, B, and C. 
Only INF A viruses are further classified by subtype on the basis of the two main surface 
glycoproteins HA and NA. INF type A viruses can infect people, birds, pigs, horses, and 
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other animals, but wild birds are the natural hosts for these viruses. INF viruses type A are 
divided into subtypes and named on the basis of two proteins on the surface of the virus: 
HA and NA. There are 16 known HA subtypes and 9 known NA subtypes and many 
different combinations of HA and NA proteins are possible. Only some INF A subtypes (i.e., 
H1N1, H1N2, and H3N2) are currently in general circulation among people, other subtypes 
are found most commonly in other animal species. For example, H7N7 and H3N8 viruses 
cause illness in horses, and H3N8 also has recently been shown to cause illness in dogs. 
Only INF A viruses infect birds, and all known subtypes of INF A viruses can infect birds. 
Typically, wild birds do not become sick when they are infected with avian INF A viruses, 
however, domestic poultry, such as turkeys and chickens, can become very sick and die 
from avian flu, and some avian INF A viruses also can cause serious disease and death in 
wild birds. Highly pathogenic avian INF A virus strains (HPAI) can cause severe illness and 
high mortality in poultry. More recently, some HPAI viruses (e.g., H5N1) have been found 
to cause no illness in some poultry, such as ducks. Avian INF A viruses of the subtypes H5 
and H7,including H5N1, H7N7, and H7N3 viruses, have been associated with HPAI, and 
human infection with these viruses have ranged from mild (H7N3, H7N7) to severe and 
fatal disease (H7N7, H5N1). In general, direct human infection with avian INFVs occurs 
very infrequently, and has been associated with direct contact (e.g., touching) infected sick 
or dead infected birds (domestic poultry). INF B viruses are usually found only in humans. 
Unlike INF A viruses, these viruses are not classified according to subtype. INF B viruses 
can cause morbidity and mortality among humans, but in general are associated with less 
severe epidemics than INF A viruses. Although INF type B viruses can cause human 
epidemics, they have not caused pandemics. INF C viruses cause mild illness in humans 
and do not cause epidemics or pandemics. These viruses are not classified according to 
subtype [22]. 
HMPV is a respiratory viral pathogen that causes a spectrum of illnesses that range from 
asymptomatic infection to severe bronchiolitis. In 2001, van den Hoogen et al described the 
identification of this new human viral pathogen from respiratory samples submitted for 
viral culture during the winter season. Half of the initial 28 hMPV isolates were cultured 
from patients younger than 1 year, and 96% were isolated from children younger than 6 
years. Seroprevalence studies revealed that 25% of all children aged 6-12 months who were 
tested in the Netherlands had detectable antibodies to hMPV; by age 5 years, 100% of 
patients showed evidence of past infection. Separate reports from all areas of the world 
support the early contention that this newly discovered virus is ubiquitous, and, like human 
respiratory RSV infection, is seasonal in nature. Although the description of this viral 
pathogen was first described in children, subsequent reports have highlighted the 
importance of hMPV as a cause of respiratory illness in adults of all ages in patients with 
cancer, in the elderly population (as a cause of serious LRTI), and in adults with underlying 
chronic medical conditions [23]. Human parainfluenza viruses (hPIV) belong to the 
Paramyxoviridae family and are negative-sense, single-stranded RNA viruses that show 
fusion and hemagglutinin-neuraminidase glycoprotein "spikes" on their surface. There are  
 
Biomedical Tissue Culture 
 
228 
four serotypes (1 through 4) and two subtypes (4a and 4b) that show different clinical and 
epidemiologic features. The virion varies in size (average diameter between 150 and 200 
nm) and shape, is unstable in the environment (surviving a few hours on environmental 
surfaces), and is readily inactivated with soap and water. HPIV are common causes of RTIs 
in infants and young children; the most distinctive clinical feature of HPIV-1 and HPIV-2 is 
croup (i.e., laryngotracheobronchitis or swelling around the vocal chords and other parts of 
the upper and middle airway); HPIV-1 is the leading cause of croup in children, whereas 
HPIV-2 is less frequently detected. HPIV-3 is more often associated with bronchiolitis 
(swelling of the small airways leading to the lungs) and pneumonia. HPIV-4 is detected 
infrequently, and is less likely to cause severe disease; but it may be more common than 
once thought. HPIVs can cause repeated infections with all serotypes throughout life. 
Reinfections usually manifested by an upper respiratory tract illness (e.g., a cold, sore 
throat). HPIVs can also cause serious LRTIs with repeat infection (e.g., pneumonia, 
bronchitis, and bronchiolitis), especially among older adults and patients with 
compromised immune systems. The incubation period (time from exposure to the virus to 
onset of symptoms) for HPIVs generally ranges from 2 to 7 days [24]. RVs are small (30 
nm), nonenveloped viruses that contain a single-strand RNA genome within an 
icosahedral (20-sided) capsid, that RV can be transmitted by aerosol or direct contact. The 
nasal mucosa is the primary site of onculation, although the conjunctiva may also be 
involved, though to a lesser extent. RVs attache their selves to the respiratory epithelium 
and spreads locally. The optimum temperature for RVs repolication is 33-35°C and so does 
not replicate efficiently at body temperature. This could be the major reason why RVs 
replicate well in the nasal passages and upper trachebronchial tree but not so well in the 
lower respiratory tract. RVs are well known for causing the common cold, although they 
have also been implicated in causing bronchitis and asthma attacks. There is little or no 
cross-protection between serotypes, making it very difficult to make vaccines. These 
viruses seems to affect children first, and then there are many modes of transmission that 
range from aerosol to direct hand-to-hand contact [25]. RSV, is a respiratory virus negative-
sense, single-stranded RNA of the family Paramyxoviridae that infects the lungs and 
breathing passages. Most otherwise healthy people recover from RSV infection in 1 to 2 
peeks. However, infection can be severe in some people, such as certain infants, young 
children, and older adults. In fact, RSV is the most common cause of bronchiolitis 
(inflammation of the small airways in the lung) and pneumonia in children under 1 year of 
age in the United States. In addition, RSV is more often being recognized as an important 
cause of respiratory illness in older adults. Initially isolated RSV from chimpanzees with 
URI as the causative agent of most epidemic bronchiolitis cases. Subsequently, RSV has 
been associated LRTIs infection in infants and multiple epidemiologic studies have 
confirmed the role of this virus as the leading cause of LRT infection in infants and young 
children. Peak of incidence of occurrence of severe RSV disease is observed at age 2-8 
months. Overall, 4-5 million children younger than 4 years acquire an RSV infection, and 
more than 125,000 children are hospitalized annually in the United States because of this 
infection. This translates to 3-9 per 1000 children younger than 1 year who are hospitalized 
annually for this condition. Virtually all children have had at least one RSV infection by 
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their third birthday. The WHO has targeted RSV for vaccine development, which is not 
surprising, given the prevalence and potential severity of this condition [26]. Other less 
common cause of viral URI is Herpes simplex virus (HSV).  
Table 1 resumes viral cusative agents of Respiratory Tract Infection (RTIs). 
Virus group Antigenic types RTIs
Rhinoviruses 100 types and  
1 subtypes 
Common Cold, Pharyngitis, Acute Laryngitis, 
Sinusitis, Acute Bronchitis, Bronchiolitis, Acute 
Pneumonia 
Coronavirus 3 or more types Common Cold, Pharyngitis, Acute Laryngitis, Acute 
Bronchitis 
Parainfluenza 
viruses 
4 types Common Cold, Pharyngitis, Acute Laryngitis, Acute 
Laryngotracheobronchitis (Croup), Sinusitis, Acute 
Bronchitis, Bronchiolitis, Acute Pneumonia 
Respiratory 
Syncytial virus 
2 types Common Cold, Acute Laryngotracheobronchitis 
(Croup), Acute Bronchitis, Bronchiolitis, Acute 
Pneumonia 
Influenza viruses 3 types Common Cold, Pharyngitis, Acute Laryngitis, Acute 
Laryngotracheobronchitis (Croup), Sinusitis, Acute 
Bronchitis, Bronchiolitis, Acute Pneumonia 
Adenoviruses 47 types Common Cold, Pharyngitis, Acute Laryngitis, 
Sinusitis, , Acute Bronchitis, Bronchiolitis, Acute 
Pneumonia 
Human 
Metapneumovirus 
 Common Cold, , Acute Laryngitis, Bronchiolitis, 
Acute Pneumonia 
Rubeola virus  Common Cold, Acute Bronchitis, Acute Pneumonia 
Enteroviruses 5 types Common cold, Pharyngitis, Acute Bronchitis, 
Bronchiolitis, Acute Pneumonia 
Rubella virus  Common cold, , Acute Bronchitis 
Varicella Zooster 
virus 
 Common Cold, Oral cavity Infections, Acute 
Pneumonia 
Herpes Simplex 
viruses 
2 types Pharyngitis, Epiglottitis, Oral cavity Infections, 
Acute Pneumonia 
Cytomegalovirus  Pharyngitis, Oral cavity Infections, Acute 
Pneumonia 
Human 
Immunodeficency 
virus  
1 type Pharyngitis 
Epstein Barr virus  Epiglottitis 
Human herpes  
virus 6 
 Acute Pneumonia 
Table 1. 
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The relative importance of individual viral agents in early life is open to debate. Certainly, 
RSV, RV, PIV, and INFV are predominant in the published data. However there are several 
factors limiting the ability to draw a definitive conclusion about which virus is the most 
common or important: differences in the way that data are collected (PCR versus 
immunoassay) between and within studies and the impact of assay sensitivity; differences in 
study design affecting age, recruitment criteria, and which viruses are studied. About viral 
aetiology and infant hospitalization due to respiratory infection, INFVs, ADV, hMPV, PIV, 
RVs, and RSV can all cause bronchiolitis, necessitating hospitalization; RSV has most 
commonly been reported to be the main cause of hospitalization due to bronchiolitis and 
increased disease severity, followed by RV and then by influenza virus and viral coinfection 
is relatively common, occurring in about 20% of cases. Even there is no consensus on the 
effect of coinfection on disease severity, coinfection with both hMPV and RSV increased the 
intensive care unit admission rate. While knowledge of which virus is predominant is 
relevant for the design of vaccines and specific prophylactic treatments, what can be 
observed is the similarity of symptoms caused by a wide range of viral agents. It may 
therefore be more appropriate to focus on ways to target the symptoms and not the agent. 
This may be especially relevant when an excess immune response causes the disease or 
when there are multiple serologically distinct subtypes circulating.  
3. Diagnosis of viral RTIs 
Respiratory viruses, that belong to several taxonomic families, show overlapping clinical 
signs and symptoms. In clinical practice, a specific virus is often not identified due to the 
lack of sensitive tests and/or the presence of as-yet-unknown pathogens [27]. Because of the 
great variety of possible pathogenic agents involved, and because of the high frequency of 
coinfections, especially among young children, whose immune system is still developing, it 
is mandatory to use diagnostic methods that allow multiple, sensitive, efficacious and rapid 
identification of all possible viruses simultaneously possibly present in the clinical sample 
[27]. Respiratory viruses have become increasingly recognized as serious causes of 
morbidity and mortality in immunocompromised patients. Rapid and sensitive detection of 
respiratory viruses is essential for early diagnosis and administration of appropriate 
antiviral therapy as well as for effective implementation of infection control measures. 
Rapid diagnosis of respiratory viruses can enable: 
- To establish a direct antiviral therapy, when available, that is crucial considering that 
antivirals are only effective if administered in the early stages of infection ;  
- To abolish unnecessary use of antibiotics, that are often prescribed to patients infected 
with respiratory viruses, with the result in no relief from symptoms and likelihood that 
antibiotic resistance will occur in concomitant bacteria ; 
- To understand the viral natural history and pathophysiology, which may allow 
physicians to better understand potential complications[28]; 
- To implement appropriate personal protective equipment and measures, such as 
quarantine of infected patients, to minimize spread and prevention of unnecessary 
isolation (often at great expense) of uninfected individuals; particularly important with 
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newly emerging or re-emerging pathogens, including severe acute respiratory 
syndrome caused by CoV, highly pathogenic avian INF and swine-origin INFV H1N1 
(S-OIV H1N1) [29]; 
- To perform accurate epidemiological studies, that allow clinicians to identify 
populations at risk and determine which populations should consider vaccination (if a 
suitable vaccine is available);  
- finally, to implement rapid viral diagnosis that significantly decreases length of hospital 
stay and unnecessary laboratory testing [30].  
However, even with the best viral detection assays currently available, a specific pathogen 
cannot be identified in 20% to 50% of RTIss. Existing viral diagnostic methods are limited in 
sensitivity and scope [31]. Several works suggest that respiratory viruses are 
underdiagnosed and they might be responsible for a considerable part of the total number 
of non characterized acquired pneumonia cases [32, 33, 34, 35, 36]. Traditional diagnostics 
methods besides being too slow, laborious and with a low sensitivity threshold, do not 
identify common viruses and high incidence viruses, like RV, or new viruses, like CoV. 
Emerging viruses like MetV or BoV recently discovered and with a very high clinical 
incidence, especially among children, are not detected neither with the use of traditional 
techniques nor with more modern methods of molecular diagnostics[37]. The discovery of 
respiratory viruses occurred initially between 1933 and 1965 when INFV, ENTV, ADV, RSV, 
RV, PINV and CoV were found by virus culture. In the 1990s, the development of high 
throughput viral detection and diagnostics instruments increased diagnostic sensitivity and 
enabled the search and the discover also of new viruses [38]. Since many respiratory viruses 
can present with similar signs and symptoms, it is impossible to differentiate one virus 
infection from another clinically. The clinician therefore relies on the laboratory to identify 
the virus. Many clinicians commonly diagnose patients syndromically with influenza or 
influenza-like illness without laboratory identification of a virus. The positive predictive 
value (PPV) of a clinical diagnosis of influenza virus infection in an adult case ranged from 
18% to 87% compared with cases of laboratory-confirmed influenza virus infection. During 
periods of high INF virus activity, a clinical diagnosis based on acute onset of high fever and 
cough can be highly predictive of influenza (PPV, 79% to 87%; negative predictive value 
[NPV], 39% to 75%). The consequences of not identifying INF virus in a nursing home or on 
a hospital ward could be catastrophic. INFVs outbreaks in a hospital can be devastating 
given the wide range of immunocompromised patients (cancer patients and transplant 
recipients) that are highly susceptible to life-threatening influenza virus infection. In either 
setting, specific antiviral agents such as M2 channel inhibitors (amantidine and rimantidine) 
or NA inhibitors (oseltamivir and zanamavir) can be prescribed; however, these drugs are 
effective only when given within the first 24 h following infection. The traditional methods 
by which respiratory viruses are routinely diagnosed: virus culture, serology, 
immunofluorescence/antigen detection, and nucleic acid/PCR-based tests. The gold 
standard for the diagnosis of respiratory virus infections, virus isolation by culture, takes 
days to weeks (shell vial assays are not available for the diagnostics of all respiratory 
viruses), and many new viruses remain unculturable [39]. Virus culture consists in infecting 
cell lines with clinical samples; virus isolation is performed using three or four cell lines and, 
together with embryonated hen eggs for INFV, provides the means for isolating respiratory  
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viruses. Tissue cultures can take up to 15 days, therefore, the infection can often be resolved 
before the infectious agent is defined. Shell vial culture (SVC), first described in the early 
1990s for murine Cytomegalovirus (CMV) is a modification of the conventional cell culture 
technique for rapid detection of viruses in vitro that involves inoculation of the clinical 
specimen on to cell monolayer grown on a cover slip in a shell vial culture tube, followed by 
low speed centrifugation and incubation. In this system the low speed centrifugation 
enhances viral infectivity to the susceptible cells because it produces a minor trauma to the 
cell surface by the low speed centrifugation mechanical force and enhances the viral entry in 
to the cells, reducing the total time taken for the virus to produce infection of cells. Shell vials 
of R-Mix, a combination of mink lung cells and human adenocarcinoma cells (strains Mv1Lu 
and A549) enable the detection of respiratory viruses from prospective clinical respiratory 
specimens [40]. The rapidity of the technique without any compromise on sensitivity has 
made SVC very popular in the field of clinical virology [41]. SVC as traditional cell culture 
assay requires specific technical and manual skills and is performed only in specialized 
laboratories. Isolation in cell culture, with the traditional method or the SVC assay is time 
consuming and have low sensitivity, but it is still considered the gold standard for the 
diagnosis of viral infections because molecular methods may not necessarily indicate that the 
virus is causing disease, viral RNA has been detected in asymptomatic children and during 
viral persistence. For these reasons traditional cell culture and SVC assay are still routinely 
used diagnostically and have a predominant role in epidemiological studies, are used to 
follow the course of an infection. A variety of serological tests including the 
hemagglutination inhibition (HAI) test, complement fixation, and enzyme immunoassay 
(EIA) are used for testing paired acute- and convalescent-phase sera for diagnosing 
infections, and in the case of INFV, HAI is able to subtype the virus as being H1 or H3 virus. 
EIAs was introduced in the 1980s and 1990s, lacks in sensitivity and is usually relegated to 
point-of-care testing in defined settings. CFT and haeagglutination-inhibition HAI techniques 
are usually used for serology. Any serological diagnosis is going to be retrospective because 
the antibody response to a viral infection can take 2 weeks to develop, but serological tests as 
cell culture assays are used in epidemiological studies. Serology assays that test blood 
samples for either virus-specific antibodies or viral antigen by a functional assay are labor-
intensive and slow to produce results. Direct fluorescent antibody (DFA) staining of cells 
derived from nasopharyngeal swabs or nasopharyngeal aspirates (NPA) became the 
mainstay for many laboratories and provide a rapid test result in about 3 h. Direct fluorescent 
antibody (DFA) but suffers from low sensitivity and is available for only a limited number of 
respiratory viruses [42]. Molecular tests are more sensitive than other diagnostic approaches, 
including virus isolation in cell culture, SVC), DFA staining, and EIA, and now form the 
backbone of clinical virology laboratory testing around the world. The polymerase chain 
reaction (PCR) is a scientific technique in molecular biology to amplify a single or a few 
copies of a piece of DNA or cDNA across several orders of magnitude, generating thousands 
to millions of copies of a particular sequences. Reverse transcription-PCR (RT-PCR), that 
produces a cDNA template from an RNA template and amplify the cDNA target is a highly 
sensitive method for diagnosis of viral infection and has been used successfully in children 
with RSV. This method was found to be 100-fold more sensitive than single-round PCR and 
was capable of detecting 0.05 PFU of tissue culture-passaged virus. Multiplex polymerase 
chain reaction (PCR) assays introduced in the last ten years to avoid separate amplifications 
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of the viruses under investigation that are resource intensive, time consuming and labor 
intensive and can detect up to 19 different viruses in a single test using numerous primer 
couples that have the same annealig temperature. Several multiplex PCR tests are now 
commercially available and tests are working their way into clinical laboratories, but the 
majority of the multiplex PCR assays have not included recently discovered respiratory 
pathogens and require validation of results by post PCR hybridization or semi/nested PCR 
which make the assay cost ineffective and increases chances of cross contamination. The 
appearance of eight new respiratory viruses, including the SARS CoV in 2003 and swine-
origin INF A/H1N1 in 2009, in the human population in the past nine years has tested the 
ability of virology laboratories to develop diagnostic tests to identify these viruses. Nucleic 
acid amplification procedures including PCR, nucleic acid sequence-based amplification 
(NASBA), and loop-mediated isothermal amplification (LAMP) were developed for most 
respiratory viruses by the end of the decade, and today, these highly sensitive NAATs are 
used in the routine clinical laboratory for detecting respiratory viruses. The profile of viruses 
detected in RTIs is changing due to the increasing use of nucleic acid-based diagnostic 
screens and the discovery of newly isolated viruses. Knowledge of the infecting agent does 
not routinely alter treatment except insofar as a positive viral identification will reduce the 
inappropriate use of antibiotics and may allow the cohorting of patients to reduce nosocomial 
infection. Several “new” viruses have been characterized, in part triggered by especially RT-
PCR. Recently isolated respiratory viral agents include human hMPV, found in samples from 
children with RSV-like bronchiolitis who were RSV negative; hBoV, discovered by a random 
PCR screen of respiratory tract samples; and two new polyomaviruses, WU and KI. The 
discovery of new agents of infection is important because they may play a role as coinfecting 
agents, altering disease severity. Newly discovered viruses may also be important in future 
outbreaks; for example, the severe acute respiratory syndrome (SARS) caused by a CoV [43]. 
Polymerase chain reaction (PCR) testing is rapid and highly sensitive. At times it seems that it 
has supplanted culture isolation as a new gold standard for the detection of respiratory 
viruses in a research setting. However, most PCR tests target only 1 virus at a time, making 
these assays cumbersome when screening a clinical specimen for all viruses that have a PCR 
test available. Moreover, reliable PCR assay need to be developed to detect or identify novel 
viruses. Molecular technology has better sensitivity and the development of multiplex 
amplifications makes it possible to detect a broader panel of viruses. ADV, PIV, hCoV, BoV 
can now be detected by multiplex assays. These assays are based on different types of 
technology, such as ligation-dependent probe amplification (MLPA1), dual priming 
oligonucleotide (DPO) technology, target specific primer extension (TSPE), or target-specific 
extension (TSE). For the simultaneous detection of up to 20 viruses, a number of multiplex 
PCR assays have been proposed [44, 45, 46, 47, 48]. It is believed that PCR has replaced tissue 
culture and serology as the gold standard for the detection of respiratory viruses owing to its 
speed, availability and versatility. Even if molecular detection has many proven advantages 
over standard virological methods, tissue culture remains an important method for detecting 
novel viral mutations within a virus population, for the detection of novel viruses and for 
phenotypic characterization of viral isolates [48]. Recently, DNA microarray testing has 
emerged as a promising new technology for broad-spectrum virus detection [49, 50, 51]. 
Panviral DNA microarrays represent the most robust approach for massively parallel viral 
surveillance and detection. The Virochip (Virochip; University of California San Francisco 
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[UCSF]) is a panviral DNA microarray capable of detecting all known viruses, as well as 
novel viruses related to known viral families in a single assay. The Virochip has been used to 
indentify SARS, Xenotropic murine leukemia virus-related (a novel Retrovirus) from patients 
with familial prostate cancer, and a novel clade of human RV [52]. The Virochip has also 
proven to be successful in a clinical veterinary setting by successfully identifying a novel CoV 
from a beluga whale held in an aquatic containment facility and by identifying foot-and-
mouth disease virus (FMDV) in ticks collected from a livestock market in Nairobi, Kenya. 
However, the usefulness and sensitivity of the Virochip platform have not been tested on 
clinical veterinary specimens [53]. In-house microarray platforms have been designed to 
detect all known viruses, as well as novel viruses related to known viral families (Virochip; 
University of California San Francisco [UCSF]). These Virochip consists of 22 000 
oligonucleotide probes representing all 1800 fully or partially sequenced viruses in GenBank 
as of Fall 2004 [54]. The performance of the Virochip in respiratory virus detection has been 
tested using virally infected tissue culture cells and in selected patient cohorts, and it 
demonstrated high sensitivity and specificity [55]. To date, the Virochip has not been 
compared directly with standard diagnostic tests for viruses in a clinical setting; thus, the 
Virochip has been compared with conventional clinical DFA- and PCR-based testing in the 
detection of respiratory viruses associated with RTIs in children [56]. We report In this study 
the analysis of 10 clinical samples from patients, with respiratory tract infection symptoms 
that resulted negative for Influenza A(H1N1)v infection, and 8 samples from Quality Control 
for Molecular Diagnostics (QCMD) with known viral load of types and subtypes of 17 
respiratory viruses, by the Clinical Array Technology (CLARTR) PneumoVir kit® (Geomica), 
a 120 spots array that make possible the specific identification of: INFV A, B and C; IPV 1, 2, 3 
and 4 (subtypes A and B); RSV type A (RSV-A) and type B (RSV-B); RV; MPV (subtypes A 
and B); ENT (Echovirus); ADV; CoV and BoV. An internal control is included, to assure that 
the amplification step is performed successfully and to avoid false negative results. We used 
a proprietary image processing software, installed in a reader (SAICLART®), that is able to 
detect and resolve the genotypes automatically, avoiding the subjectivity that may introduce 
the user interaction, and provide fast, accurate and reproducible results. All samples have 
been analyzed three times and all results have been confirmed by single virus RT PCR 
(Roche) and Light Cycler, Roche, detector. All viruses detected by PneumoVir kit in the 
analyzed samples have been confirmed by RT PCR (Roche), in some cases at a sensitivity 
level higher than what was declared from the manufacturer. We detected single infection 
with: RSVA, MPV A, Coronavirus 229. One coinfection of MPV A, RSV A, RSV B, one 
coinfection of Corona 229, IPV3, RSV A, and one coinfection of BoV, MPV A. Only in the 
sample with the coinfection Corona 229, IPV3, RSV A, the Real Time PCR did not confirm the 
presence of IPV3 genome. Therefore we believe that the CLART can readily detect respiratory 
viruses in various clinical respiratory samples (pharyngeal and nasal swabs, nasopharyngeal 
lavage, pharyngeal exudates). The signal intensity increased according to the viral titer. These 
data directly correlate sample viral titers with the successful detection by the CLART and 
highlight the importance of sensitivity when utilizing the Virochip platform in a clinical 
settings. The CLART positively identified respiratory viruses in the all QCMD samples 
randomly mixed demonstrating high specificity inside the range of the sensitivity of the 
method. Together, the data in this report demonstrate that the CLART can successfully detect 
respiratory viruses frequently found in human respiratory swabs. The ability of the CLART 
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to positively detect viruses with a high degree of genetic variance, as is found in the 
specimens tested here, is a benefit that may outweigh concerns regarding costs and 
turnaround time. Furthermore, the advantages in the technical effort, cost, and turnaround 
time involved in using the CLART as a viral discovery platform far exceed those of next-
generation sequencing platforms. In conclusion CLART provides, at very competitive cost, a 
system capable of detecting and identifying simultaneously several respiratory viruses, in 
clinical specimens with high sensitivity and specificity.  
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